Abstract
METHODS:
After digestion with Hind III and Xba I, the U6 promoter and VEGFR 2 siRNA were cloned into the promoterless shuttle vector to construct pShuttle-mU6pro-VEGFR 2 siRNA. Then the product vector was cotransformed with adenovirus backbone containing plasmid pAdeasy1to produce pAdeasy-mU6pro-VEGFR 2 siRNA by homologous recombinantion. Finally the human colorectal cancer LOVO cells were infected with the recombinant adenovirus and the VEGFR 2 expression was examined using Western-blot.
RESULTS:
The pAdeasy-mU6pro-VEGFR 2 siRNA was successfully constructed. VEGFR 2 siRNA mediated by the adenovirus significantly inhibited the expression of VEGFR 2 in LOVO cell lines (P <0.01).
CONCLUSION:
The pAdeasy-mU6pro-VEGFR 2 siRNA can effectively down-regulate VEGFR 2 expression in LOVO cell line, which lays the foundation for gene therapy of colorectal cancer. The data are shown in Table 1 . . .
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